Quantcast

Latest Dendreon Stories

2011-05-02 15:00:00

SEATTLE, May 2, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2011. Revenue for the quarter ended March 31, 2011 was $28.1 million compared to $21,000 for the quarter ended March 31, 2010.

2011-04-29 08:00:00

VANCOUVER, British Columbia, April 29, 2011 /PRNewswire-Asia/ -- Insiderslab.com issues new research reports that highlight large insider trade found in for Micron, AT&T, Discovery, Apple, Amarin, & Dendreon.

2011-04-28 05:00:00

SEATTLE, April 28, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: Deutsche Bank Annual Health Care Conference, Boston, MA on May 4, 2011 at 8:40 a.m.

2011-04-20 08:15:00

SAN FRANCISCO, April 20, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) ("the Company")and maintains its twelve month target price of $6.50.

2011-04-14 05:00:00

SEATTLE, April 14, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, May 2, 2011 at 4:30 p.m.

2011-04-06 07:00:00

SEATTLE, April 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the American Association of Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida: Wednesday, April 6, 2011, 8:00 a.m. - 12:00 p.m. ET.

2011-04-02 00:00:28

New advances in treatment for prostate disease are a chief focus of Harvard Medical School’s 2011 Annual Report on Prostate Diseases. Boston, MA (Vocus/PRWEB) April 01, 2011 New advances in treatment for prostate disease are a chief focus of Harvard Medical School’s 2011 Annual Report on Prostate Diseases.

2011-03-30 17:35:00

SEATTLE, March 30, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the Centers for Medicare and Medicaid Services (CMS) has issued a proposed decision memo for PROVENGE® (sipuleucel-T).

2011-03-22 15:15:00

NEW YORK, March 22, 2011 /PRNewswire/ -- A study in the prostate cancer space completed this week by ITG's Majestic Market Research reveals that Amgen's (Nasdaq: AMGN) Xgeva (a.k.a.

2011-03-10 13:17:00

SEATTLE, March 10, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the U.S.


Word of the Day
begunk
  • To befool; deceive; balk; jilt.
  • An illusion; a trick; a cheat.
The word 'begunk' may come from a nasalised variant of Scots begeck ("to deceive, disappoint"), equivalent to be- +‎ geck.